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Abstract 
 
Pathogen inactivation technologies are known to alter in vitro phenotype and functional properties of platelets. 
Because pathogen inactivation generates reactive oxygen species, oxidative stress is considered as one of 
the plausible cause at the origin of the platelet storage lesion acceleration after treatment. To date proteomics 
has been used to document the protein variations to picture out the impact. Here, platelet concentrates were 
prepared from buffy-coats in Intersol additive solution, leukoreduced and pathogen inactivated using a 
riboflavin/UVB treatment. At day 2 of storage the platelet proteomes of control (untreated) and treated platelet 
concentrates were investigated against the site specific oxidation by liquid chromatography coupled to tandem 
mass spectrometry in a shotgun experiment. The shotgun approach detected 9350 peptides (and 2534 
proteins) of which 1714 were oxidized. Eighteen peptides were found exclusively oxidized in treated platelets 
whereas 3 peptides were only found oxidized in control. The present data evidenced an interference with 
several proteins involved in platelet aggregation and platelet shape change (such as talin and vinculin). 
 
Keywords: Pathogen Inactivation, Platelet concentrate, Oxidation, Proteomics, Riboflavin, ROS, Shotgun 
 
Résumé 
Les traitements d’inactivation des pathogènes sont connus pour induire, in vitro, des modifications au niveau 
du phénotype et des fonctionnalités plaquettaires. De par le caractère oxydatif de ces traitements 
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photochimiques, la génération d’espèces réactives de l’oxygène est l’une des causes possibles du 
vieillissement accéléré des concentrés plaquettaires inactivés. Les analyses protéomiques ont montré jusqu’à 
présent les variations de certaines protéines suite à ces traitements. Dans la présente étude, des concentrés 
plaquettaires ont été préparés à partir de buffy-coat en solution Intersol, leucoréduits et traités pour 
l’inactivation des pathogènes à base de riboflavine/UVB. Deux jours après le don, des oxydations spécifiques 
du protéome des plaquettes traitées et non-traitées (contrôle) ont été étudiés par chromatographie liquide 
couplée à la spectrométrie de masse. L’approche « shotgun » utilisée a détecté 9350 peptides (pour 2534 
protéines) dont 1714 étaient oxydés. Dix-huit d’entre eux ont été détectés exclusivement dans les plaquettes 
traitées et 3 exclusivement dans le contrôle. Ces données montrent l’impact de ces oxydations de protéines 
impliquées dans des processus d’agrégation plaquettaire et de changement de forme (telles la talin et la 
vinculin). 
 
Mots clés : Concentré plaquettaire, Espères réactives de l’oxygène, Inactivation des pathogènes, Oxydation, 
Protéomique, Riboflavine, Shotgun 
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1 Introduction 
Pathogen inactivation technologies (PITs) provide a higher level of safety in transfusion medicine but impact 
the quality of blood products [1]. They reduce platelets in vitro functionality [2-6], suggesting that in addition to 
early platelet storage lesions [7] there is an endogenous factor affecting their effectiveness. PITs enhance 
storage lesions and correlate with platelet aging and pre-activation [8, 9]. Hypotonic shock response 
highlighted lower deformability and flow cytometry evidenced increased pre-apoptotic markers, degranulation 
and integrins activation [3, 10]. In addition, glycolytic metabolism is accelerated resulting in medium 
acidification [6]. Despite these considerations, in vitro functionality tests are difficult to be translated in vivo 
and have not a clear clinical relevance to date [11-13].  
PI produces ROS that can damage other molecules than DNA/RNA , such as peptides and proteins 
[14, 15]. For instance, ROS imbalance enhances protein carbonylation, a hallmark of oxidation, as recently 
shown in Mirasol-treated platelet concentrates (PCs). The production of hydrogen peroxide on days 5 and 7 
was also significantly higher in treated samples, suggesting a decreased antioxidant cell defense and/or 
enhanced activation pathways due to second messengers. This was also evidenced in Intercept-treated 
platelets where antioxidant power was decreased [16] and where ROS-induced urate conversion into allantoin 
was observed [17]. At the protein level, the impact should mainly be post-translational such as oxidations [14, 
15], since PI-platelets are able to synthesize proteins [18]. 
Considering that (i) proteomic data have reported protein damages [19], (ii) post-translational 
analyses are missing and (iii) functional properties (linked to protein functions) are altered (eg reduced 
response to hypothonic shock and increase adhesion to fibrinogen, Figure 1) [3], mass spectrometry (MS)-
based proteomics were applied to look at oxidative damages. Although literature reports a relatively mild 
impact of PITs on platelet proteome [2, 7-9, 19-21], several protein-based pathways were found to be affected 
by PITs [19, 20, 22, 23]. In the present study, the impact of riboflavin/UVB on platelet proteome was 
investigated by a shotgun approach with a focus on irreversible oxidations. 
 
2 Methods 
2.1 Platelet concentrates 
The experiments were composed by three biological replicates prepard as follows. Buffy coat-derived and 
leukoreduced PCs were prepared and treated as previously described in Intersol [3]. Then three ABO-
matched PCs were pooled together in a 2L-Plasma bag, agitated for 5 min and split in three identical PCs: 
one control bag (untreated PC) was supplemented with 17.5 mL of Intersol, and one treated bag was 
completed with 17.5 mL of riboflavin and treated in home-made illuminator (addition of riboflavin followed by a 
UVB treatment at 5J/cm2 applied in 20 min) [3]. PCs were stored overnight in a storage bag (1300 mL, 
PL2410 plastic) under agitation at 22°C, and sampling were done at day 2 post-donation. The third bag was 
not employed here.  
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2.2 Proteomics 
Five µL aliquots of Prostaglandin E1 (PGE1) (> 98%, HPLC grade) from Sigma Aldrich (Steinheim, Germany) 
were diluted in 495 µL of Tyrode’s buffer. Four mL of PCs were sampled in plastic tubes through sterile 
connection at day 2 and transferred to a 15-mL tube containing 40 µL of PGE1 1%. PCs were incubated 
during 5 min at 37 °C under gentle rotation and followed by 10 min of centrifuge at 1’000g at room 
temperature (RT). The supernatant was carefully removed and the pellet was washed several times. Platelets 
were resuspended in 1 mL of Tyrode’s buffer + 10 µL PGE1 and samples were aliquoted at 50 µg. Aliquots 
were centrifuged (1’000g) at RT during 10 min and pellets were frozen at -80°C. 150 µL Laemmli 2x were 
added to the pellet for proteomics. 
Proteins (8 µg) were separated on a 12% mini polyacrylamide gel (BioRad), excised in 6 gel bands 
(Supplementary Fig. S1) and digested with sequencing-grade Trypsin/LysC (Promega) [24]. Extracted 
peptides were vacuum-dried and resuspended in 0.05% trifluoroacetic acid, 2% (v/v) acetonitrile for LC-
MS/MS analyses on a Dionex RSLC 3000 nanoHPLC system (Dionex, Sunnyvale, CA, USA) interfaced via a 
nanospray source to a high resolution mass spectrometer QExactive Plus (Thermo Fisher, Bremen, Germany) 
(see Supplementary Material for details).  
2.3 Data analysis 
Protein identification from MS raw files and label-free quantitation with MaxQuant version 1.5.3.30 [25] were 
realized as previously described [26], using the set of Homo sapiens proteome sequences downloaded from 
UniProt database (UP000005640_9606.fasta, December 2015 version, 21’026 sequences). Trypsin was used 
as the enzyme definition, allowing 2 missed cleavages. Database searches were carried out with a parent ion 
tolerance of 5 ppm after recalibration, and a fragment ion mass tolerance of 20 ppm. Variable modifications 
were specified as follows: N-terminal acetylation of protein, iodoacetamide derivative of cysteine, dioxidation 
and trioxidation of cysteine, oxidation and dioxidation of methionine and tryptophan, tryptophan oxidation to 
kynurenin. Both peptide and protein FDR rates were set at 1% as calculated against a decoy sequence 
database and the match between runs function was activated. 
 Protein pathways were analyzed on string-db.org (version 10.0, access on May 2016). 
2.4 Statistical analysis  
Oxidation levels were compared by combining moderated t-test (limma) with rank products on well-defined 
null hypothesis. A p-value < 0.05 is considered as significant. 
 
3 Results 
First of all, 2D gel-based proteomics was carried out as for Intercept-treated PCs [9]. It revealed a low impact 
on the proteome (in particular the overexpression of glyoxalase domain-containing protein 4 in treated 
samples) and identified proteins were not confirmed by western blot (see supplementary material). 
Label free shotgun analysis of the samples at day 2 was carried out. A total of 2534 proteins (3700 
are reported to date [27]) with a minimum of two peptides were detected (see Supplementary Table 1). 
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Although a considerable absolute number of oxidized peptides (1714) was detected, in general, identified 
proteins and relative peptides showed mitigate matching with our peptide-based oxidation database [14] and 
mainly contained methionine oxidation. Particularly, 18 peptides belonging to 17 proteins were found to be 
only oxidized in treated samples, while 3 proteins were only oxidized in control ones (Table 1, upper part). 
Protein-protein interactions analysis identified that the platelet aggregation was particularly affected by 
oxidation (unique biological process with a false discovery < 0.05, Table 2 and Supplementary Fig. S4). 
Comparison of oxidation levels between treated and untreated PCs did not present differences, after 
classic statistical correction (i.e. Benjamini-Hochberg). However, treated samples displayed an oxidative 
tendency suggesting slight irreversible oxidation induced by PITs. Without the correction, several oxidized 
peptides (45) displayed higher intensity in treated samples and 8 oxidized peptides were more intense in 
control samples (p-value < 0.01). Therefore, to fully explored the dataset and to further gain statistical 
significance (considering the list of oxidized peptides > 1’000 rows and the presence of missing values [not all 
the peptides were detected in all samples]), moderated t-test (limma) with rank produ ts on well-defined null 
hypothesis were combined according to Schwämmle et al. [28]. Hence, an increased significance for 18 
peptides (allowing a maximum of two modifications per peptide) was obtained. Surprisingly, the majority of the 
significantly oxidized peptides (i.e. 11 peptides) belong to control PCs (Table 1, lower part). 
 
4 Discussion 
The present identification number of 2534 proteins is high which make difficult to explore all the potential 
modifications. Therefore, and this is one limitation of our approach, we have tp target on specific amino acids 
in order to find statistical variation. Therefore, three amino acids were preferentially selected. Methionine and 
cysteine are well known protein antioxidant and stabilize the protein structure [29]. In addition, they are 
involved to numerous biological processes as redox system. The choice of the third amino acid tryptophan 
was based on a previous study on PI-treated model peptides because of its high sensitivity to ROS [14]. 
Although a considerable absolute number of oxidized peptides were detected (1714 over 9350 
detected peptides), only 18 and 3 oxidized peptides were found in treated and untreated samples, 
respectively (while the unmodified peptides were present in all replicates of both conditions) (Table 1, upper 
part). Such findings make us plaid for a slight increase of irreversible oxidation in riboflavin/UVB-treated 
platelet proteome. However, while in control PCs no significant enrichment was observed, at least 4 impacted 
proteins of treated PCs belong to the same biological process that is the aggregation. In addition, several 
proteins overlap cytoskeleton, focal adhesion and degranulation platelet apparatus. Of interest, talin and 
vinculin, involved in platelet shape change, were already reported to be affected by riboflavin/UVB treatment 
[19, 22] which might explain the decreased in platelet integrity as shown by hypotonic shock response (see 
Figure 1a) [3]. 
Looking for the oxidation of peptides present in both conditions, the analysis showed increased 
oxidation in control peptides (11 peptides versus 7). An intriguing subset of proteins is composed by 14-3-3Z 
and GPIbα. Following the binding of vWF to GPIb-IX-V, 14-3-3Z directly interacts with GPIb-IX-V cytoplasmic 
domain [30], which also showed an increased oxidation in treated samples. GPIb-IX-V is involved in platelet 
primary function by binding vWF. Protein oxidation could impair the response to vWF. Fibrinogen gamma 
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chain (FGG) was also up-oxidized in treated samples. FGG is secreted from platelets through alpha granules 
and carries the main binding site for αIIbβ3. In addition, it has to be taken into account that FGG is present in 
plasma, and oxidized FGG can originate from the plasma contamination. FGG in plasma is probably more 
exposed to the oxidative stress generated during the PI than the one present in the platelet cytoplasm 
(indeed, endogenous ROS are clearly attenuated when plasma concentration increase, data not shown). By 
the same way, myosin contains two different up-oxidized peptides in treated PCs. Interestingly, myosin tightly 
interacts with actin, which in turn is significantly down-oxidized. Indeed actin cluster is present with two 
different oxidized peptides. Actin oxidation is part of a complex system regulating the dynamic of F-actin 
assembly and disassembly. Actin irreversible oxidation is known to disassemble and inhibit the formation of 
new F-actin, favoring crosslinks, aggregates and disordered structures in different cells [31]. Inversely, actin 
reversible oxidation of cysteines (e.g. Cys272 and Cys374) constitutes an important oxidative stress sensor 
for apoptosis signaling inside cells and directly participate to F-actin elongation [32]. Here, by untargeted 
experiment, Cys217 was more oxidized in control PCs forming a sulfinic acid (R-SO2H). This cysteine seems 
to participate in a lesser extent to F-actin formation, even though it was already detected in reversible oxidized 
form [33]. PF4 peptide AGPHCPTAQLIATLK is present in two different oxidized cysteine forms: R-SO2H and 
R-SO3H. Interestingly such irreversible oxidation disrupts disulfide bond between Cys41 and Cys67. PF4 
protein is released during aggregation and inhibits anticoagulant heparin effect. Here again it is surprising to 
find higher oxidation in untreated samples. Another intriguing case is GAPDH methionine carbonylation that 
could impair glycolysis even though direct conclusions are not feasible since the glycolysis is accelerated after 
PI [3, 6].  
The impact of PI on platelet proteome was reported to be moderate [19] and the current data are in 
agreement with recently published analyses on Mirasol-treated PCs [34] and fill in previous data [19]. These 
irreversible protein oxidations cannot explain by themselves the cellular and functional lesions observed 
despite the focus on aggregation pathways (i.e. GPIb) and platelet shape change. Redox protein activities are 
known to be regulated via ROS. Indeed, reversible oxidations represent subtle changes that should be studied 
in details by proteomics [35], as in the case of the redox sensitive cysteines that can transiently be oxidized by 
second messengers during platelet signaling [36]. 
 
5 Conclusions 
In vitro functional properties of platelets have been reported to be altered by riboflavin/UVB treatment, which 
migh be explained by protein modifications. The present shotgun experiment detected a low number of 
irreversibly oxidized proteins after riboflavin/UVB treatment. It evidenced an interference with several proteins 
involved in platelet aggregation and platelet shape change. The protein oxidations and modifications are part 
of the factors governing treatment-dependent PCs in vitro functionality and further in-depth investigations will 
be required such as redox signaling [35]. 
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Figure 1 caption 
 
Fig. 1. Functional properties of riboflavin/UVB treated platelet compared to untreated platelets. (a) Hypotonic 
shock response is statistically decreased after treatment. (b) Static adhesion to fibrinogen is higher after 
treatment. * p-value < 0.05; *** p-value < 0.001. These data extracted from ref [3] were obtained with the 
same riboflavin/UVB procedure. 
 
 
. 
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Table 1: List of oxidized peptides in riboflavin/UVB-treated and untreated PCs at day 2. 1st part: oxidation 
observed only in one condition. 2nd part: differences in expression. The mean intensity differences are 
represented as “treated – control”.  
 
Presence only in one condition 
 Accession number Protein Name Sequence Modification 
MS/MS 
count Mean 
C
on
tro
l 
P62820;Q9H0U4;Q
92928 
Ras-related protein Rab-1A;Ras-related 
protein Rab-1B;Putative Ras-related protein 
Rab-1C 
QWLQEIDR Kynurenin 2 na 
Q13418 Integrin-linked protein kinase FALDMAR Oxidation (M) 1 na 
P68032;P68133 Actin, alpha cardiac muscle 1;Actin, alpha skeletal muscle 
YPIEHGIITNWDDMEKIWHHTFYN
ELR 2 Oxidation (W) 1 na 
Tr
ea
te
d 
Q9Y490 Talin-1 LHTDDELNWLDHGR Dioxidation (MW) 4 na 
P23229 Integrin alpha-6 LNYLDILMR Oxidation (M) 4 na 
P60174 Triosephosphate isomerase FFVGGNWK Oxidation (W) 3 na 
Q86UX7 Fermitin family homolog 3 FIQAWQSLPDFGISYVMVR Oxidation (W) 3 na 
Q00610 Clathrin heavy chain 1 LLEMNLMHAPQVADAILGNQMFTHYDR Dioxidation (MW) 3 na 
P46109 Crk-like protein YPSPPMGSVSAPNLPTAEDNLEYVR Oxidation (M) 3 na 
Q13011 Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial 
DHSVAESLNYVASWNMSMLQTQ
DLVK 2 Oxidation (M) 2 na 
O00429 Dynamin-1-like protein LDLMDAGTDAMDVLMGR Oxidation (M) 2 na 
Q9Y490 Talin-1 LHTDDELNWLDHGR Kynurenin 2 na 
P14625 Endoplasmin EAVEKEFEPLLNWMK Oxidation (M) 1 na 
Q9Y696 Chloride intracellular channel protein 4 EMTGIWR Oxidation (M) 1 na 
P50416 Carnitine O-palmitoyltransferase 1, liver isoform 
GPLMVNSNYYAMDLLYILPTHIQA
AR Oxidation (M) 1 na 
P46459 Vesicle-fusing ATPase GSMAGSTGVHDTVVNQLLSK Oxidation (M) 1 na 
P18206 Vinculin LANVMMGPYRQDLLAK Oxidation (M) 1 na 
Q13418 Integrin-linked protein kinase LNENHSGELWK Oxidation (W) 1 na 
P54819 Adenylate kinase 2, mitochondrial LVSDEMVVELIEK Oxidation (M) 1 na 
P0DMV9;P0DMV8 Heat shock 70 kDa protein 1B;Heat shock 70 kDa protein 1A 
MKEIAEAYLGYPVTNAVITVPAYF
NDSQR Oxidation (M) 1 na 
Q8WUM4 Programmed cell death 6-interacting protein TMQGSEVVNVLK Oxidation (M) 1 na 
Difference in expression 
 Accession number Protein Name Sequence Modification 
MS/MS 
count Mean 
C
on
tro
l 
Q9P1F3 Costars family protein MNVDHEVNLLVEEIHR Acetyl (Protein N-term);Oxidation (M) 4 
-
1.412 
Q13418 Integrin-linked protein kinase MYAPAWVAPEALQK Oxidation (M) 15 -1.487 
P10720;P02776 
Platelet factor 4 variant;Platelet factor 4 
variant(4-74);Platelet factor 4 variant(5-
74);Platelet factor 4 variant(6-74);Platelet 
factor 4;Platelet factor 4, short form 
AGPHCPTAQLIATLK Trioxidation (C) 7 -1.501 
P10720;P02776 Platelet factor 4 variant AGPHCPTAQLIATLK Dioxidation (C) 4 -1.660 
P37802 Transgelin-2 YGINTTDIFQTVDLWEGK Kynurenin (W) 6 -1.737 
Q96BM9;Q9NVJ2 ADP-ribosylation factor-like protein 8A;ADP-ribosylation factor-like protein 8B EKDNIDITLQWLIQHSK Dioxidation (MW) 1 
-
1.808 
P04406 Glyceraldehyde-3-phosphate dehydrogenase VVDLMAHMASK Oxidation (M) 14 -2.025 
P12814 Alpha-actinin-1 QFGAQANVIGPWIQTK Dioxidation (MW) 3 -2.170 
P27105* Erythrocyte band 7 integral membrane protein VIAAEGEMNASR Oxidation (M) 13 -2.519 
P63261 Actin, cytoplasmic 2 EKLCYVALDFEQEMATAASSSSLEK Dioxidation (C) 2 
-
3.143 
P18206 Vinculin LANVMMGPYR 2 Oxidation (M) 1 -4.265 
e a t  P07359 Platelet glycoprotein Ib alpha chain AMTSNVASVQCDNSDKFPVYK Carbamidomethyl (C);Oxidation (M) 11 1.982 
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P19105;P24844;O1
4950 
Myosin regulatory light chain 12A;Myosin 
regulatory light polypeptide 9;Myosin 
regulatory light chain 12B 
DGFIDKEDLHDMLASLGK Dioxidation (MW) 5 2.058 
P02679 Fibrinogen gamma chain MLEEIMK Oxidation (M) 13 2.146 
P23284 Peptidyl-prolyl cis-trans isomerase B VIKDFMIQGGDFTR Dioxidation (MW) 1 2.218 
P19105;P24844;O1
4950 
Myosin regulatory light chain 12A;Myosin 
regulatory light polypeptide 9;Myosin 
regulatory light chain 12B 
ELLTTMGDR Dioxidation (MW) 2 2.839 
P68032;P63267;P6
2736;P68133 
Actin, alpha cardiac muscle 1;Actin, gamma-
enteric smooth muscle;Actin, aortic smooth 
muscle;Actin, alpha skeletal muscle 
YPIEHGIITNWDDMEK Kynurenin 8 3.278 
P31946 14-3-3 protein beta/alpha;14-3-3 protein beta/alpha, N-terminally processed 
TAFDEAIAELDTLNEESYKDSTLIM
QLLR Oxidation (M) 3 4.970 
* Probable contamination from residual red blood cells. 
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Table 2: Protein-protein interactions analysis of the 17 proteins containing 18 oxidized peptides in 
riboflavin/UVB-treated PCs at day 2. Platelet aggregation was the only biological process with a false 
discovery < 0.05. 
Biological Process 
#pathway ID pathway description count in gene set false discovery rate 
GO.0070527 platelet aggregation 4 2.98E-04 
Cellular component 
#pathway ID pathway description count in gene set false discovery rate 
GO.0005925 focal adhesion 7 1.09E-05 
GO.0030055 cell-substrate junction 6 1.52E-04 
GO.0030054 cell junction 8 3.07E-04 
GO.0070062 extracellular exosome 11 3.58E-04 
GO.0044421 extracellular region part 12 5.48E-04 
GO.0044430 cytoskeletal part 8 6.61E-04 
GO.0005829 cytosol 11 9.65E-04 
GO.0031988 membrane-bounded vesicle 11 1.96E-03 
GO.0005576 extracellular region 12 2.23E-03 
GO.0042995 cell projection 8 0.00223 
GO.0005856 cytoskeleton 8 0.00546 
GO.0042470 melanosome 3 6.96E-03 
GO.0043034 costamere 2 9.66E-03 
GO.0005911 cell-cell junction 4 0.0124 
GO.0015629 actin cytoskeleton 4 2.16E-02 
GO.0043198 dendritic shaft 2 3.09E-02 
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